Stephen M. Bloch, serving as a director at Liquidia Corp (NASDAQ:LQDA), has disclosed the sale of common stock valued at approximately $6.05 million. This disclosure was made through a recent Form 4 filing submitted to the Securities and Exchange Commission. The divestment activity spanned two trading days, July 6 and July 7, 2026, with execution prices falling within the $80.175 to $81.3128 per share range. This transaction occurs against the backdrop of the stock trading near its 52-week high of $82, a level reached after the company recorded a substantial 536% return over the preceding twelve months.
The initial transaction took place on July 6, where Bloch reported the sale of 25,000 shares at a weighted average price of $80.175. These shares were disposed of through multiple trades, with individual sale prices fluctuating between $80.00 and $80.32. Subsequent activity on July 7 involved two distinct transactions. The first of these comprised the sale of 22,718 shares at a weighted average price of $80.4833, with prices ranging from $80.00 to $80.995. The second transaction on the same day resulted in the disposal of 27,282 shares at a weighted average price of $81.3128, with individual sale prices spanning from $81.00 to $81.78.
Despite the reported insider sale, data suggests the stock may still present undervaluation opportunities, with further insights available to subscribers. All reported sales were classified as indirect holdings, held by Canaan VIII L.P. Canaan Partners VIII LLC serves as the sole general partner of Canaan L.P., and investment and voting decisions are managed by the managers of Canaan LLC. Bloch has disclaimed beneficial ownership of these securities, except to the extent of his pecuniary interest, and did not participate in the investment decision due to a communications-screen policy.
Following these transactions, Bloch’s indirect ownership in Liquidia Corp stands at 780,073 shares. Additionally, he directly holds 71,594 shares of Liquidia Corp common stock. In other recent developments, Liquidia Corporation announced its addition to the S&P SmallCap 600 Index, effective June 22, 2026. This inclusion reflects the company’s market capitalization, liquidity, and profitability criteria as assessed by S&P Dow Jones Indices. On the financial front, Liquidia’s drug Yutrepia has surpassed launch expectations, leading BofA Securities to increase its peak sales estimate from $1.7 billion to $2.2 billion. Despite this positive outlook, BofA downgraded Liquidia’s stock rating from Buy to Neutral, citing a more balanced risk-reward profile after recent gains.
Meanwhile, H.C. Wainwright raised its price target for Liquidia to $75, maintaining a Buy rating, following a Supreme Court ruling with favorable implications for the company’s legal case. Similarly, Raymond James reiterated a Strong Buy rating with a $68 price target, also highlighting the positive impact of the Supreme Court’s decision. These developments underscore significant interest and activity surrounding Liquidia’s legal and market performance.